Wednesday, June 10, 2026

pharma Β· Schizophrenia Β· Alzheimer's Disease Psychosis Β· ACAD

Acadia Pharmaceuticals

Acadia Pharmaceuticals clinical programs β€” 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Indianapolis, USA HQ
17 Employees
Public company Type
ACAD Β· NYSE Ticker
Company details
Intelligence Β· Clinical Programs

Acadia Pharmaceuticals projects

11 ClinicalTrials.gov programs sponsored by Acadia Pharmaceuticals.

Acadia Pharmaceuticals has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ACP-204

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 3 small molecule active

    2 trials
  2. ACP-204

    Acadia Pharmaceuticals B.V.

    Lewy Body Dementia Psychosis

    phase 3 small molecule active

    2 trials
  3. Carbetocin

    Acadia Pharmaceuticals B.V.

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials
  4. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 3 small molecule completed

    4 trials
  5. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials
  6. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials
  7. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials
  8. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials
  9. Placebo

    Acadia Pharmaceuticals B.V.

    Dementia-related Psychosis

    phase 3 small molecule completed

    1 trial
  10. Trofinetide

    Acadia Pharmaceuticals B.V.

    Rett Syndrome

    phase 3 small molecule completed

    4 trials
  11. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Acadia Pharmaceuticals have?

11 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.